Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss

Stock Track

03/13

VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.

The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.

The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1163636636"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163636636\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163636636?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163636636","market":"nz","top_or_hot":-1,"title":"Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss","media":"Stock Track","content":"<p>VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.</p><p>The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.</p><p>The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | VISEN PHARMA-B Soars 5.28% Intraday on Regulatory Approval and Commercialization Plans Despite Annual Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-13 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.</p><p>The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.</p><p>The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维升药业-B","start_time":0,"source_url":"","article_id":"1163636636","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163636636","pubTimestamp":1773365728,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.The stock movement comes after the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维升药业-B"},"translate_title":"个股追踪|维森制药-B盘中大涨5.28%尽管年度亏损仍获监管批准及商业化计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (02561) surged 5.28% during intraday trading on Friday, showing strong investor confidence despite the company reporting an annual loss.The stock movement comes after the company announced its annual results, which included a loss of RMB253.4 million for the year. However, investors appear to be focusing on positive regulatory developments, particularly the approval of the Biologics License Application for Lonapegsomatropin for Injection in China on January 26, 2026.The company plans to fully launch the commercialization of this long-acting growth hormone treatment in 2026, which has demonstrated superior height growth efficacy compared to daily growth hormone injections in clinical trials. Additionally, the company has established strategic partnerships, including a Commercial Supply Framework Agreement with Ascendis Pharma and a cooperation agreement with Dongfulong Technology Group, to advance its drug pipeline and technology transfer efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}